Cargando…
Is Adherence to Imatinib Mesylate Treatment Among Patients with Chronic Myeloid Leukemia Associated with Better Clinical Outcomes in Qatar?
BACKGROUND: Despite the revolutionary success of introducing tyrosine kinase inhibitors (TKIs), such as imatinib mesylate (IM), for treating chronic myeloid leukemia (CML), a substantial proportion of patients’ treatments fail. AIM: This study investigates the correlation between patient adherence a...
Autores principales: | Al-Dewik, Nader I., Morsi, Hisham M., Samara, Muthanna M., Ghasoub, Rola S., Gnanam, Cinquea C., Bhaskaran, Subi K., Nashwan, Abdulqadir J., Al-Jurf, Rana M., Ismail, Mohamed A., AlSharshani, Mohammed M., AlSayab, Ali A., Ben-Omran, Tawfeg I., Khatib, Rani B., Yassin, Mohamed A. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Libertas Academica
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5047706/ https://www.ncbi.nlm.nih.gov/pubmed/27721664 http://dx.doi.org/10.4137/CMO.S32822 |
Ejemplares similares
-
Aberrant DNA methylation of PTPRG as one possible mechanism of its under‐expression in CML patients in the State of Qatar
por: Ismail, Mohamed A., et al.
Publicado: (2020) -
Effects of consanguinity in a cohort of subjects with certain genetic disorders in Qatar
por: Ben‐Omran, Tawfeg, et al.
Publicado: (2019) -
Studying the Impact of Presence of Alpha Acid Glycoprotein and Protein Glycoprotein in Chronic Myeloid Leukemia Patients Treated with Imatinib Mesylate in the State of Qatar
por: Al-Dewik, Nader I., et al.
Publicado: (2015) -
Association of single nucleotide polymorphisms with dyslipidemia and risk of metabolic disorders in the State of Qatar
por: Al‐Sharshani, Dalal, et al.
Publicado: (2023) -
The Impact of Ethnicity on the Response to Eltrombopag in Patients With Immune Thrombocytopenia (ITP) in Qatar: A Single Institution Experience
por: Yassin, Mohamed A, et al.
Publicado: (2022)